French biotech Genfit shifts gears after Phase III NASH failure July 23, 2020 Auto Bot BioPharma, biopharma nl, Diagnostics, France, NASH, nonalcoholic steatohepatitis 0 The company said it was formally terminating the Phase III study of the drug elafibranor in NASH and refocus its development of the drug on another disease, primary biliary cholangitis, as well as a diagnostic for NASH.